CorMedix to Acquire Substantially All Heron Therapeutics Assets
The transaction adds four commercial-stage products to CorMedix’s hospital- and acute-care-focused platform. Consideration includes $145 million in cash, subject to customary purchase price adjustments, plus 14,583,333 CorMedix shares.
Story updates
12:17:02 PM UTC
SquawkNews
CorMedix agreed to acquire substantially all of Heron's assets for $145M cash, subject to customary adjustments, plus 14,583,333 shares valued at approximately $77.6M based on CorMedix's Nov. 6 closing price. Up to $55M in earn-outs and royalties are additional.Material DetailsContext by AI Analyst…
Adds four commercial-stage products — ZYNRELEF®, APONVIE®, CINVANTI® and SUSTOL® — to CorMedix's hospital- and acute-care-focused commercial platformUpfront consideration consisting of $145 million in cash, subject to customary purchase price adjustments, plus 14,583,333 shares of CorMedix common s…